Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - Observational prospective single institution analysis.

Múdry, Peter; Kýr, Michal; Rohleder, Ondrej; Mahdal, Michal; Staniczková Zambo, Iva; Jezová, Marta; Tomás, Tomás; Sterba, Jaroslav

Múdry, Peter; Kýr, Michal; Rohleder, Ondrej; Mahdal, Michal; Staniczková Zambo, Iva; Jezová, Marta; Tomás, Tomás; Sterba, Jaroslav.

Afiliación

Múdry P; Department of Paediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Cernopolni 9, Brno 613 00, Czech Republic.
Kýr M; International Clinical Research Centre, St. Anne's University Hospital Brno, Pekarska 53, Brno 656 91, Czech Republic.
Rohleder O; Department of Paediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Cernopolni 9, Brno 613 00, Czech Republic.
Mahdal M; International Clinical Research Centre, St. Anne's University Hospital Brno, Pekarska 53, Brno 656 91, Czech Republic.
Staniczková Zambo I; Department of Paediatric Oncology, University Hospital Brno and School of Medicine, Masaryk University, Cernopolni 9, Brno 613 00, Czech Republic.
Jezová M; International Clinical Research Centre, St. Anne's University Hospital Brno, Pekarska 53, Brno 656 91, Czech Republic.
Tomás T; 1 Department of Orthopaedics, St. Annés University Hospital Brno and School of Medicine, Masaryk University, Pekarska 53, Brno 613 00, Czech Republic.
Sterba J; 1 Department of Pathology, St. Anne's University Hospital Brno and School of Medicine, Masaryk University, Pekarska 53, Brno 613 00, Czech Republic.

J Bone Oncol ; 28: 100362, 2021 Jun.

Article en En | MEDLINE | ID: mdl-33948428

Palabras clave

A/AP, adriamycin (doxorubicin)/adriamycin (doxorubicin) and cisplatin; AIC, Akaike information criterion; BIC, Bayesian information criterion; CI, confidence interval; CTCAE, common terminology criteria for adverse events; Comparative analysis; EFS, event free survival; EMA, European Medicines Agency; FDA, Food and Drug Administration; HR, hazard ratio; LY, lymphocytes; M/F, male/female; MFS, metastatic free survival; MONO, monocytes; MTX, methotrexate; Mifamurtide; NEU, neutrophiles; Osteosarcoma; PFS, progression free survival; PLT, platelets; R0 and R1 resection, free margins and microscopic rest after resection respectively; SD, standard deviation; Single institution analysis; Survival

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Bone Oncol Año: 2021 Tipo del documento: Article País de afiliación: República Checa

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google